PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial, page-781

It is highly likely (best educated guess) that Australian Grant to "Fight MND" could be announced end of July but I have nothing to support that. The SPP I reckon is oversubscribed. We'll know that PAA at current price is significantly undervalued, without the management reshuffle, I would never had a change for entry below 20C.

Because of unmet nature of drugs required "NOW" to treat MND and what MPL demonstrated in Ph 1 and over the already approved FDA drugs are incomparable. There result is no-match (3 months vs 3-5 years of life extension) and more importantly its competitors are nowhere near what MPL results show. If the same p-values as Ph1 can be achieved in Ph2/3, I believe no one is stopping PAA to become >$1B MC company. Having said that it will take time (12-15 months) then boom but you need to have patience to ride through peak and trough.

DYOR it is not a buy or sell advice.